Abgeschlossene Studien

2013

Ascierto, P.A. et al.MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Publische Online February 2013,
http://dx.doi.org/10.1016/S1470-2045(13)70024-X, PDF

2014

Dummer, R. et al.Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. (PDF)
McArthur, G.A. et al.Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (PDF)
​Rodon, J. et al.
​A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. (PDF)
​Dreno, B. et al.
​TG1042 (Adenovirus-interferon-c) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. (PDF)
​Dummer R. et al.
​Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). (PDF)

2015

​Robert, C. et al.
​Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. (PDF)
​Goldinger S.M. et al.
​A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. (PDF)
​Urosevic-Maiwald, M. et al.
​In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. (PDF)
​Eggermont A.M.M. et al.
​Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (PDF)
​Basset-Seguin, N. et al.
​Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. (PDF)
​Migden, M.R., et al.
​Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. (PDF)
​Larkin, J. et al.
​Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (PDF)
​Ribas, A. et al.
​Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (PDF)


Wir verwenden Cookies, um unsere Website nutzerfreundlich zu gestalten, sie fortlaufend zu verbessern und die Zugriffe auf unsere Website zu analysieren. Mit der Nutzung unserer Dienste erklären Sie sich damit einverstanden. Weitere Informationen finden Sie in unserer Datenschutzerklärung.